With informed and creative minds we innovate novel small molecule modulators to become next-generation breakthrough therapies for life threatening conditions.Learn More
Our platform gives us the power to identify and develop allosteric modulators that targets disease-related proteins in novel ways.
Beactica's fragment-based drug discovery platform is based on state-of-the-art SPR biosensor technology that is augmented by proprietary compound collections, methodology, algorithms and experimental designs. This powerful combination enables us to achieve pioneering goals beyond the expected.
Beactica's CEO, Dr Per Källblad, gives presentation entitled "Targeting LSD1 in aggressive brain tumors" at Nordic Life Science Days (NLSDays) in Stockholm (10-12 Sep 2018)
Sign up for the Beactica newsletter to receive our latest news and updates